MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.

ABSTRACT:

Background

Primary systemic treatment for ovarian cancer is surgery, followed by platinum based chemotherapy. Platinum resistant cancers progress/recur in approximately 25% of cases within six months. We aimed to identify clinically useful biomarkers of platinum resistance.

Methods

A database of ovarian cancer transcriptomic datasets including treatment and response information was set up by mining the GEO and TCGA repositories. Receiver operator characteristics (ROC) analysis was performed in R for each gene and these were then ranked using their achieved area under the curve (AUC) values. The most significant candidates were selected and in vitro functionally evaluated in four epithelial ovarian cancer cell lines (SKOV-3-, CAOV-3, ES-2 and OVCAR-3), using gene silencing co

SUBMITTER: Penzvalto Z 

PROVIDER: S-EPMC4247127 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature